NEW DELH: Uttarakhand on Monday
suspended
the manufacturing
licenses
of 14
products
made by Baba Ramdev’s Patanjali Ayurveda ltd and Divya Pharmacy with immediate effect.
The state licensing authority informed in an affidavit that the cancellation order was issued for “repeated violations” of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
“The SLA issued an order, dated April 15, 2024, to Divya Pharmacy and Respondent No.
5-Patanjali Ayurved Ltd., stating therein that the manufacturing licenses for 14 of their products, namely ‘Swasari Gold’, ‘Swasari Vati, Bronchom’, ‘Swasari Pravahi’, ‘Swasari Avaleh’, ‘MuktaVati Extra Power’, ‘Lipidom’, ‘Bp Grit’, ‘Madhugrit’, ‘MadhunashiniVati Extra Power’, ‘Livamrit Advance’, ‘Livogrit’, ‘Eyegrit Gold’ and ‘Patanjali Drishti Eye Drop’, are suspended with immediate effect under Rule 159(1) of The Drugs and Cosmetics Rules, 1945,” it said.
“The District Ayurvedic and Unani Officer, Haridwar filed a criminal complaint before the Chief Judicial Magistrate, Haridwar against Swami Ramdev, Acharya Balkrishna, Divya Pharmacy and Patanjali Ayurved Limited under Sections 3, 4 and 7 of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954,” the affidavit added.Earlier, the Supreme Court, hearing a case on misleading ads by Patanjali Ayurveda, had asked the Ramdev-owned company to issue a public apology in newspapers same size in which it advertises its products.
Here are the products facing action:
| Swasari Gold |
| Swasari Vati |
| Bronchom |
| Swasari Pravahi |
| Swasari Avaleh |
| MuktaVati Extra Power |
| Lipidom |
| Bp Grit |
| Madhugrit |
| MadhunashiniVati Extra Power |
| Livamrit Advance |
| Livogrit |
| Eyegrit Gold |
| Patanjali Drishti Eye Drop |
The SC deferred hearing on contempt proceedings against Patanjali founders Ramdev and Balkrishna as they could not file affidavit on public apology published in newspapers.
The SC had also told Indian Medical Association (IMA) that while it was pointing fingers at Patanjali, four fingers were pointing at them. “Your doctors also endorsing medicines in the allopathic field. If that’s happening, why should we not turn the beam at you?”
The next hearing is scheduled for Tuesday.
